REG - AstraZeneca PLC - Result of AGM

AstraZenecaAnnouncement

11/04/2025 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250411:nRSK7701Ea&default-theme=true

RNS Number : 7701E  AstraZeneca PLC  11 April 2025

11 April 2025

 

Results of Annual General Meeting held on 11 April 2025

 

AstraZeneca PLC announced the results of the voting at its Annual General
Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were
decided by poll vote. Resolutions 9 - 12 were passed as special resolutions;
all other resolutions were passed as ordinary resolutions.

 

     Resolution                                                                      Votes for      % of votes cast  Votes against  % of votes cast  Votes cast in total  Total votes cast as a % of issued share capital  Votes withheld
 1   To receive the Company's Accounts, the Reports of the Directors and Auditor     1,192,725,049  99.89            1,302,321      0.11             1,194,027,370        77.00                                            3,895,442
     and the Strategic Report for the year ended 31 December 2024
 2   To confirm the 2024 interim dividends                                           1,195,017,493  99.91            1,103,545      0.09             1,196,121,038        77.14                                            1,801,779
 3   To re-appoint PricewaterhouseCoopers LLP as Auditor                             1,188,274,693  99.35            7,772,140      0.65             1,196,046,833        77.13                                            1,875,089
 4   To authorise the Directors to agree the remuneration of the Auditor             1,194,967,897  99.91            1,035,521      0.09             1,196,003,418        77.13                                            1,919,068
 5a  To re-elect Michel Demaré as a Director                                         1,192,597,854  99.72            3,348,956      0.28             1,195,946,810        77.13                                            1,975,799
 5b  To re-elect Pascal Soriot as a Director                                         1,194,161,249  99.85            1,828,809      0.15             1,195,990,058        77.13                                            1,932,568
 5c  To re-elect Aradhana Sarin as a Director                                        1,193,240,137  99.77            2,730,661      0.23             1,195,970,798        77.13                                            1,951,782
 5d  To re-elect Philip Broadley as a Director                                       1,192,344,687  99.70            3,578,792      0.30             1,195,923,479        77.12                                            1,999,129
 5e  To re-elect Euan Ashley as a Director                                           1,193,753,030  99.82            2,163,488      0.18             1,195,916,518        77.12                                            2,006,023
 5f  To elect Birgit Conix as a Director                                             1,195,603,172  99.97            315,680        0.03             1,195,918,852        77.12                                            2,003,690
 5g  To elect Rene Haas as a Director                                                1,173,872,808  98.16            22,033,446     1.84             1,195,906,254        77.12                                            2,016,215
 5h  To elect Karen Knudsen as a Director                                            1,195,604,027  99.97            301,466        0.03             1,195,905,493        77.12                                            2,017,116
 5i  To re-elect Diana Layfield as a Director                                        1,195,604,497  99.97            300,003        0.03             1,195,904,500        77.12                                            2,018,109
 5j  To re-elect Anna Manz as a Director                                             1,194,823,605  99.91            1,048,387      0.09             1,195,871,992        77.12                                            2,050,618
 5k  To re-elect Sheri McCoy as a Director                                           1,149,796,685  96.15            46,101,055     3.85             1,195,897,740        77.12                                            2,024,865
 5l  To re-elect Tony Mok as a Director                                              1,195,574,262  99.97            310,802        0.03             1,195,885,064        77.12                                            2,037,477
 5m  To re-elect Nazneen Rahman as a Director                                        1,193,299,249  99.79            2,566,024      0.21             1,195,865,273        77.12                                            2,057,343
 5n  To re-elect Marcus Wallenberg as a Director                                     980,843,680    83.11            199,351,215    16.89            1,180,194,895        76.11                                            17,727,254
 6   To approve the annual statement of the Chair of the Remuneration Committee and  1,152,784,239  96.40            43,097,131     3.60             1,195,881,370        77.12                                            2,041,421
     the Annual Report on Remuneration for the year ended 31 December 2024
 7   To authorise limited political donations                                        1,152,744,556  96.90            36,841,029     3.10             1,189,585,585        76.72                                            8,336,892
 8   To authorise the Directors to allot shares                                      1,108,802,235  92.72            87,039,743     7.28             1,195,841,978        77.12                                            2,080,506
 9   To authorise the Directors to disapply pre-emption rights                       1,057,501,935  88.45            138,089,003    11.55            1,195,590,938        77.10                                            2,331,672
 10  To authorise the Directors to further disapply pre-emption rights for           1,011,405,311  84.89            179,961,211    15.11            1,191,366,522        76.83                                            6,556,062
     acquisitions and specified capital investments
 11  To authorise the Company to purchase its own shares                             1,186,436,265  99.24            9,028,112      0.76             1,195,464,377        77.10                                            2,458,408
 12  To reduce the notice period for general meetings                                1,109,717,539  92.81            85,989,258     7.19             1,195,706,797        77.11                                            2,216,021

 

Deborah DiSanzo and Andreas Rummelt retired from the Board at the conclusion
of the AGM. For the purposes of section 430(2B) of the Companies Act 2006,
they will receive their pro-rata entitlement to non-executive director fees
for the month of April 2025. No other remuneration payment or payment for loss
of office will be made.

A copy of the resolutions passed at the AGM (other than resolutions concerning
ordinary business) has been submitted to the National Storage Mechanism for
publication, and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Issued capital

As at 9 April 2025, the number of issued shares of the Company was
1,550,636,615 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against all of the resolutions at the
AGM. In accordance with the Company's Articles of Association, on a poll every
member present in person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca) .

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGPUGCCUPAGAG